trending Market Intelligence /marketintelligence/en/news-insights/trending/IARBwg5c-WKHSdBVNNvauQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Pacgen, General Biologicals add new markets for P113 products


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Pacgen, General Biologicals add new markets for P113 products

Pacgen Life Science Corp. partner General Biologicals Corp. added new markets for P113 oral and general hygiene products licensed from Pacgen.

The P113 mouth rinse and mouth sprays will be made available in southern China in addition to their existing markets in Taiwan, subject to regulatory approval.

General Biologicals entered into an agreement with Dongguan Biotech Industrial Development Co. to distribute its oral hygiene and hepatitis-testing products. It granted Dongguan Biotech exclusive right to distribute its products in the Guangdong Province.

In exchange for the regional distribution right, General Biologicals will receive up to 4.5 million Chinese yuan of milestone payments for the first year. Pacgen is entitled to royalties based on sales of P113 products, in accordance with its licensing agreement with General Biologicals.

As of Jan. 23, US$1 was equivalent to 6.86 yuan.